AI in Drug Discovery Market Forecast Report, 2021-2031

AI in Drug Discovery Market (Offering: Software and Services; Application: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Metabolic Diseases, Cardiovascular Diseases, and Others; Technology: Machine Learning and Other Technologies; Drug Type: Small Molecules and Large Molecules; and End User: Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academics & Research, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Artificial Intelligence (AI) Help Find Novel Treatments for COVID-19 Patients

Quick drug identification for COVID-19 could serve as a boon, as many countries struggle to contain the deadly virus. Lockdowns and stringent restrictions on the movement of people have had a negative impact, including tremendous losses incurred by companies in the AI in drug discovery market. However, if proper treatment is found for treating COVID-19 patients, it could help in many ways. A University of Michigan research team has used an AI-powered image to identify over 17 existing drugs to reduce coronavirus infection in cells. Such methods and techniques help discover the efficacy of existing drugs against COVID-19, ultimately contributing to the growth of the AI in drug discovery market.

ai in drug discovery market infographic

Request a sample to get extensive insights into the AI in Drug Discovery Market

Rise in Incidence of Chronic Diseases Propels Need for AI in Drug Discovery

The incidence of chronic diseases is increasing at a rapid pace across the globe. According to the Centers for Disease Control and Prevention (CDC), six in 10 adults in the U.S. have a chronic disease, and four in 10 adults have two or more. Furthermore, the CDC also highlights that chronic diseases such as heart disease and diabetes are the leading causes of death in the U.S. Such statistics shed light on the growing prevalence of chronic diseases and the need to bring down the fatality rate caused due to these diseases.

AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases. Thus, these factors will led to considerable growth of the AI in drug discovery market during the forecast period of 2021-2031.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Profound Impact of Oncology on Market Growth

The role of AI in oncology is estimated to offer significant growth opportunities. AI can help the researchers understand how cancer cells become resistant to anticancer drugs, eventually leading to drug development and adjust drug use. AI technologies such as machine learning can act as a catalyst in existing anticancer drug research.

Paige’s, an AI diagnostic technology startup is a classic instance of the rising advancements in the oncology segment. The company uses machine learning to enable pathologists to facilitate precise cancer diagnoses through the images of tissue samples. Such developments are expected to fuel the growth of the AI in drug discovery market.

Popularity of Mindful AI to Offer Breakthrough Opportunities

Mindful AI is a fast emerging ideal solution for developing drugs in a more human-centric and responsible manner. Mindful AI is an intention-based approach used for creating effective AI-based technologies. With mindful AI, pharmaceutical companies can not only know about how quickly a drug can be developed but also about how inclusive it is in terms of effectiveness. Thus, the growing popularity of mindful AI in the pharmaceutical industry will present promising growth opportunities, thus driving the overall AI in drug discovery market.

Advancements in Treatment of Neurological Diseases to Open Profitable Avenues

The use of AI in treating neurological disorders could present an array of growth opportunities. Various players in the pharmaceutical industry are collaborating for exploring novel neurological diseases solutions. PharmEnable, the U.K.-based drug discovery company and Sosei, a Japan-based firm, are collaborating to use the Sosei Heprares CPCR-focused drug design platform and PharmEnable’s AI technologies to discover drug leads. Similar developments will assure extensive growth for the AI in drug discovery market.

ai in drug discovery market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on AI in Drug Discovery Market

Analysts’ viewpoint

The AI in drug discovery market is estimated to expand at a CAGR of 36.1% during the forecast period of 2021-2031. The global market is projected to cross US$ 10.93 Bn by 2031. The cases of chronic diseases, especially cardiovascular disorders and diabetes, are increasing at an accelerated rate, eventually boosting the need for AI in drug discovery platforms. Furthermore, the use of AI in treating neurological disorders will help in increasing the growth rate. Players in the AI in drug discovery market should focus on using Mindful AI to design and develop effective drug discovery platforms. Furthermore, advancements made by AI in findings related to COVID-19 are anticipated to witness substantial growth.

AI in Drug Discovery Market: Overview

  • Artificial intelligence (AI) has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as deep learning, machine learning, or artificial neural networks) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, increase productivity while simultaneously enhancing treatment and patient throughput.
  • Artificial intelligence in healthcare is booming, and with the limitless possibilities offered by this cutting-edge technology, a slew of business behemoths are investing in healthcare applications. Integration of AI and machine learning tools in drug discovery & development applications could enhance healthcare outcomes by increasing drug discovery efficiency, facilitating targeted molecule identification, minimizing drug discovery timeframes, and, most importantly, lowering drug development costs for drug manufacturers.
  • Moreover, various pharmaceutical firms and entrepreneurs across the world are launching projects and investing in the creation of AI and machine learning technologies for bettering drug discovery and improving drug development outcomes

AI in Drug Discovery: Market Drivers

  • Increase in cross-industry alliances and collaborations drives the global AI for drug discovery market. Rise in relevance of AI in drug discovery & development and surge in funding for R&D activities, including AI technology in the field of drug research, are projected to propel the global market.
    • In July 2020, IBM acquired WDG Automation to advance AI-Infused Automation Capabilities for Enterprises. This acquisition advances IBM's comprehensive AI-infused automation capabilities, spanning business processes to IT operations.
  • Artificial intelligence (AI) drug discovery company Exscientia expanded its ongoing anti-viral drugs partnership with the U.K.’s national synchrotron facility Diamond Light Source and the University of Oxford across the Atlantic Ocean to include California-based Scripps Research’s Calibr and focus on COVID-19 research.
    • In January 2021, Nucleai, the U.S.-based provider of biomarkers-based therapy, signed a collaboration agreement with Debiopharm Pharma Company, a pioneer in drug development. According to the terms of the agreement, Debiopharm Pharma Company will use Nucleai’s artificial intelligence (AI) platform for its pipeline oncology drug candidates.
  • Hence, increase in cross-industry collaborations and partnerships drives the global AI in drug development market

Market Segmentation: AI in Drug Discovery Market

  • In terms of drug type, the global AI in drug discovery market has been bifurcated into large molecules and small molecules
  • Based on application, the global AI in drug discovery market has been classified into oncology, infectious diseases, neurological disorders, rare diseases, metabolic diseases, cardiovascular diseases, and others
  • In terms of end user, the global AI in drug discovery market has been divided into pharmaceutical & biotechnology companies, contract research organizations, academics & research, and others
  • Based on offering, the global AI in drug discovery market has been split into software and services
  • In terms of technology, the global AI in drug discovery market has been segregated into machine learning and other technologies
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The AI in drug discovery market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: AI in Drug Discovery Market

  • In terms of region, the global AI in drug discovery market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America is projected to account for the largest share of the global AI for drug discovery market in the near future, as the region is technologically advanced and one of the early adopters of latest technologies. High awareness about AI in drug discovery among the key players in the region is another driver of the global AI for drug discovery market.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the global AI in drug discovery market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Major Players

  • The AI in drug discovery market report concludes with the company profiles section, which includes key information about major players in the global AI in drug discovery market
  • Leading players analyzed in the report include
    • Exscientia
    • GNS Healthcare
    • Cloud Pharmaceuticals, Inc.
    • Benevolent AI
    • PathAI, Inc.
    • Berg Health
    • Atomwise
    • Insitro
    • Cyclica
    • BlackThorn Therapeutics
    • Insilico Medicine
    • Notable Labs
    • Standigm
    • Recursion Pharmaceuticals
    • BioSymetrics
  • Each of these players has been profiled in the AI in drug discovery market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

AI in Drug Discovery Market – Segmentation

TMR’s study on the global AI in drug discovery market includes information divided into six segments: offering, technology, drug type, application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global AI in drug discovery market are discussed in detail.

Drug Type
  • Small Molecules
  • Large Molecules
Application
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Rare Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Others
Technology
  • Machine Learning
  • Other Technologies
Offering
  • Software
  • Services
End User
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academics & Research
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of AI in drug discovery market?

AI in drug discovery market is projected to reach US$ 10.93 Bn By 2031

What is the anticipated CAGR of the AI in drug discovery market in the forecast period?

AI in drug discovery market is anticipated to expand at a CAGR of 36.1% during the forecast period

What are the key driving factors for the growth of the AI in drug discovery market?

AI in drug discovery market is driven by increase in pressure on drug manufacturers to reduce drug prices, rise in prevalence of lifestyle diseases and increase in healthcare expenditure

Which is the rising prominent segment in the AI in drug discovery market?

The machine learning segment held significant share of the AI in drug discovery market

Who are the key players in the global AI in drug discovery market?

Top Key players in AI in drug discovery market are Exscientia, GNS Healthcare, Cloud Pharmaceuticals, Inc., Benevolent AI, PathAI, Inc., BlackThorn Therapeutics, Insilico Medicine, Notable Labs, Standigm, Recursion Pharmaceuticals, and BioSymetrics

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global AI in Drug Discovery Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Introduction

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global AI in Drug Discovery Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

        5.2. Technological Advancements

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid /long term impact)

    6. Global AI in Drug Discovery Market Analysis and Forecast, by Offering

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Offering, 2017–2031

            6.3.1. Software

            6.3.2. Services

        6.4. Market Attractiveness Analysis, by Offering

    7. Global AI in Drug Discovery Market Analysis and Forecast, by Technology

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Technology, 2017–2031

            7.3.1. Machine Learning

            7.3.2. Other Technologies

        7.4. Market Attractiveness Analysis, by Technology

    8. Global AI in Drug Discovery Market Analysis and Forecast, by Drug Type

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Drug Type, 2017–2031

            8.3.1. Small Molecules

            8.3.2. Large Molecules

        8.4. Market Attractiveness Analysis, by Drug Type

    9. Global AI in Drug Discovery Market Analysis and Forecast, by Application

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Application, 2017–2031

            9.3.1. Oncology

            9.3.2. Infectious Diseases

            9.3.3. Neurological Disorders

            9.3.4. Rare Diseases

            9.3.5. Metabolic Diseases

            9.3.6. Cardiovascular Diseases

            9.3.7. Others

        9.4. Market Attractiveness Analysis, by Application

    10. Global AI in Drug Discovery Market Analysis and Forecast, by End-user

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast, by End-user, 2017–2031

            10.3.1. Pharmaceutical & Biotechnology Companies

            10.3.2. Contract Research Organizations

            10.3.3. Academics & Research

            10.3.4. Others

        10.4. Market Attractiveness Analysis, by End-user

    11. Global AI in Drug Discovery Market Analysis and Forecast, by Region

        11.1. Key Findings

        11.2. Market Value Forecast, by Region

            11.2.1. North America

            11.2.2. Europe

            11.2.3. Asia Pacific

            11.2.4. Latin America

            11.2.5. Middle East & Africa

        11.3. Market Attractiveness Analysis, by Country/Region

    12. North America AI in Drug Discovery Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Offering, 2017–2031

            12.2.1. Software

            12.2.2. Services

        12.3. Market Value Forecast, by Technology, 2017–2031

            12.3.1. Machine Learning

            12.3.2. Other Technologies

        12.4. Market Value Forecast, by Drug Type, 2017–2031

            12.4.1. Small Molecules

            12.4.2. Large Molecules

        12.5. Market Value Forecast, by Application, 2017–2031

            12.5.1. Oncology

            12.5.2. Infectious Diseases

            12.5.3. Neurological Disorders

            12.5.4. Rare Diseases

            12.5.5. Metabolic Diseases

            12.5.6. Cardiovascular Diseases

            12.5.7. Others

        12.6. Market Value Forecast, by End-user, 2017–2031

            12.6.1. Pharmaceutical & Biotechnology Companies

            12.6.2. Contract Research Organizations

            12.6.3. Academics & Research

            12.6.4. Others

        12.7. Market Value Forecast, by Country, 2017–2031

            12.7.1. U.S.

            12.7.2. Canada

        12.8. Market Attractiveness Analysis

            12.8.1. By Offering

            12.8.2. By Technology

            12.8.3. By Drug Type

            12.8.4. By Application

            12.8.5. By End-user

            12.8.6. By Country

    13. Europe AI in Drug Discovery Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Offering, 2017–2031

            13.2.1. Software

            13.2.2. Services

        13.3. Market Value Forecast, by Technology, 2017–2031

            13.3.1. Machine Learning

            13.3.2. Other Technologies

        13.4. Market Value Forecast, by Drug Type, 2017–2031

            13.4.1. Small Molecules

            13.4.2. Large Molecules

        13.5. Market Value Forecast, by Application, 2017–2031

            13.5.1. Oncology

            13.5.2. Infectious Diseases

            13.5.3. Neurological Disorders

            13.5.4. Rare Diseases

            13.5.5. Metabolic Diseases

            13.5.6. Cardiovascular Diseases

            13.5.7. Others

        13.6. Market Value Forecast, by End-user, 2017–2031

            13.6.1. Pharmaceutical & Biotechnology Companies

            13.6.2. Contract Research Organizations

            13.6.3. Academics & Research

            13.6.4. Others

        13.7. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.7.1. Germany

            13.7.2. U.K.

            13.7.3. France

            13.7.4. Italy

            13.7.5. Spain

            13.7.6. Rest of Europe

        13.8. Market Attractiveness Analysis

            13.8.1. By Offering

            13.8.2. By Technology

            13.8.3. By Drug Type

            13.8.4. By Application

            13.8.5. By End-user

            13.8.6. By Country/Sub-region

    14. Asia Pacific AI in Drug Discovery Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Offering, 2017–2031

            14.2.1. Software

            14.2.2. Services

        14.3. Market Value Forecast, by Technology, 2017–2031

            14.3.1. Machine Learning

            14.3.2. Other Technologies

        14.4. Market Value Forecast, by Drug Type, 2017–2031

            14.4.1. Small Molecules

            14.4.2. Large Molecules

        14.5. Market Value Forecast, by Application, 2017–2031

            14.5.1. Oncology

            14.5.2. Infectious Diseases

            14.5.3. Neurological Disorders

            14.5.4. Rare Diseases

            14.5.5. Metabolic Diseases

            14.5.6. Cardiovascular Diseases

            14.5.7. Others

        14.6. Market Value Forecast, by End-user, 2017–2031

            14.6.1. Pharmaceutical & Biotechnology Companies

            14.6.2. Contract Research Organizations

            14.6.3. Academics & Research

            14.6.4. Others

        14.7. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.7.1. Japan

            14.7.2. China

            14.7.3. India

            14.7.4. Australia & New Zealand

            14.7.5. Rest of Asia Pacific

        14.8. Market Attractiveness Analysis

            14.8.1. By Offering

            14.8.2. By Technology

            14.8.3. By Drug Type

            14.8.4. By Application

            14.8.5. By End-user

            14.8.6. By Country/Sub-region

    15. Latin America AI in Drug Discovery Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Offering, 2017–2031

            15.2.1. Software

            15.2.2. Services

        15.3. Market Value Forecast, by Technology, 2017–2031

            15.3.1. Machine Learning

            15.3.2. Other Technologies

        15.4. Market Value Forecast, by Drug Type, 2017–2031

            15.4.1. Small Molecules

            15.4.2. Large Molecules

        15.5. Market Value Forecast, by Application, 2017–2031

            15.5.1. Oncology

            15.5.2. Infectious Diseases

            15.5.3. Neurological Disorders

            15.5.4. Rare Diseases

            15.5.5. Metabolic Diseases

            15.5.6. Cardiovascular Diseases

            15.5.7. Others

        15.6. Market Value Forecast, by End-user, 2017–2031

            15.6.1. Pharmaceutical & Biotechnology Companies

            15.6.2. Contract Research Organizations

            15.6.3. Academics & Research

            15.6.4. Others

        15.7. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.7.1. Brazil

            15.7.2. Mexico

            15.7.3. Rest of Latin America

        15.8. Market Attractiveness Analysis

            15.8.1. By Offering

            15.8.2. By Technology

            15.8.3. By Drug Type

            15.8.4. By Application

            15.8.5. By End-user

            15.8.6. By Country/Sub-region

    16. Middle East & Africa AI in Drug Discovery Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Offering, 2017–2031

            16.2.1. Software

            16.2.2. Services

        16.3. Market Value Forecast, by Technology, 2017–2031

            16.3.1. Machine Learning

            16.3.2. Other Technologies

        16.4. Market Value Forecast, by Drug Type, 2017–2031

            16.4.1. Small Molecules

            16.4.2. Large Molecules

        16.5. Market Value Forecast, by Application, 2017–2031

            16.5.1. Oncology

            16.5.2. Infectious Diseases

            16.5.3. Neurological Disorders

            16.5.4. Rare Diseases

            16.5.5. Metabolic Diseases

            16.5.6. Cardiovascular Diseases

            16.5.7. Others

        16.6. Market Value Forecast, by End-user, 2017–2031

            16.6.1. Pharmaceutical & Biotechnology Companies

            16.6.2. Contract Research Organizations

            16.6.3. Academics & Research

            16.6.4. Others

        16.7. Market Value Forecast, by Country/Sub-region, 2017–2031

            16.7.1. GCC Countries

            16.7.2. South Africa

            16.7.3. Rest of Middle East & Africa

        16.8. Market Attractiveness Analysis

            16.8.1. By Offering

            16.8.2. By Technology

            16.8.3. By Drug Type

            16.8.4. By Application

            16.8.5. By End-user

            16.8.6. By Country/Sub-region

    17. Competition Landscape

        17.1. Market Player - Competition Matrix (by tier and size of companies)

        17.2. Market Share Analysis/Ranking, by Company, 2020

        17.3. Company Profiles

            17.3.1. Exscientia

                17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.1.2. Company Financials

                17.3.1.3. Growth Strategies

                17.3.1.4. SWOT Analysis

            17.3.2. GNS Healthcare

                17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.2.2. Company Financials

                17.3.2.3. Growth Strategies

                17.3.2.4. SWOT Analysis

            17.3.3. Cloud Pharmaceuticals, Inc.

                17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.3.2. Company Financials

                17.3.3.3. Growth Strategies

                17.3.3.4. SWOT Analysis

            17.3.4. Benevolent AI

                17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.4.2. Company Financials

                17.3.4.3. Growth Strategies

                17.3.4.4. SWOT Analysis

            17.3.5. PathAI, Inc.

                17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.5.2. Company Financials

                17.3.5.3. Growth Strategies

                17.3.5.4. SWOT Analysis

            17.3.6. Berg Health

                17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.6.2. Company Financials

                17.3.6.3. Growth Strategies

                17.3.6.4. SWOT Analysis

            17.3.7. Atomwise

                17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.7.2. Company Financials

                17.3.7.3. Growth Strategies

                17.3.7.4. SWOT Analysis

            17.3.8. Insitro

                17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.8.2. Company Financials

                17.3.8.3. Growth Strategies

                17.3.8.4. SWOT Analysis

            17.3.9. Cyclica

                17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.9.2. Company Financials

                17.3.9.3. Growth Strategies

                17.3.9.4. SWOT Analysis

            17.3.10. BlackThorn Therapeutics

                17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.10.2. Company Financials

                17.3.10.3. Growth Strategies

                17.3.10.4. SWOT Analysis

            17.3.11. Insilico Medicine

                17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.11.2. Company Financials

                17.3.11.3. Growth Strategies

                17.3.11.4. SWOT Analysis

            17.3.12. Notable Labs

                17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.12.2. Company Financials

                17.3.12.3. Growth Strategies

                17.3.12.4. SWOT Analysis

            17.3.13. Standigm

                17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.13.2. Company Financials

                17.3.13.3. Growth Strategies

                17.3.13.4. SWOT Analysis

            17.3.14. Recursion Pharmaceuticals

                17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.14.2. Company Financials

                17.3.14.3. Growth Strategies

                17.3.14.4. SWOT Analysis

            17.3.15. BioSymetrics

                17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.15.2. Company Financials

                17.3.15.3. Growth Strategies

                17.3.15.4. SWOT Analysis

    List of Tables

    Table 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Offering, 2017–2031

    Table 02: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 03: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 04: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 05: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 06: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

    Table 09: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

    Table 10: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 11: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

    Table 12: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

    Table 15: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

    Table 16: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 17: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

    Table 18: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 19: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

    Table 21: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

    Table 22: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 23: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

    Table 24: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 25: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 26: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

    Table 27: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

    Table 28: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 29: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

    Table 30: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 31: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 32: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

    Table 33: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

    Table 34: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 35: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

    Table 36: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global AI in Drug Discovery Market Value Share, by Offering, 2020

    Figure 03: Global AI in Drug Discovery Market Value Share, by Technology, 2020

    Figure 04: Global AI in Drug Discovery Market Value Share, by Drug Type, 2020

    Figure 05: Global AI in Drug Discovery Market Value Share, by Application, 2020

    Figure 06: Global AI in Drug Discovery Market Value Share, by End-user, 2020

    Figure 07: Global AI in Drug Discovery Market Value Share, by Indication, 2020

    Figure 08: Global AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 09: Global AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

    Figure 10: Global AI in Drug Discovery Market Value (US$ Mn), by Software, 2017–2031

    Figure 11: Global AI in Drug Discovery Market Value (US$ Mn), by Services, 2017–2031

    Figure 12: Global AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 13: Global AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

    Figure 14: Global AI in Drug Discovery Market Value (US$ Mn), by Machine Learning, 2017–2031

    Figure 15: Global AI in Drug Discovery Market Value (US$ Mn), by Other Technologies, 2017–2031

    Figure 16: Global AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 17: Global AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 18: Global AI in Drug Discovery Market Value (US$ Mn), by Small Molecules, 2017–2031

    Figure 19: Global AI in Drug Discovery Market Value (US$ Mn), by Large Molecules, 2017–2031

    Figure 20: Global AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 21: Global AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 22: Global AI in Drug Discovery Market Value (US$ Mn), by Oncology, 2017–2031

    Figure 23: Global AI in Drug Discovery Market Value (US$ Mn), by Infectious Diseases, 2017–2031

    Figure 24: Global AI in Drug Discovery Market Value (US$ Mn), by Neurological Disorders, 2017–2031

    Figure 25: Global AI in Drug Discovery Market Value (US$ Mn), by Rare Diseases, 2017–2031

    Figure 26: Global AI in Drug Discovery Market Value (US$ Mn), by Metabolic Diseases, 2017–2031

    Figure 27: Global AI in Drug Discovery Market Value (US$ Mn), by Cardiovascular Diseases, 2017–2031

    Figure 28: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031

    Figure 29: Global AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 30: Global AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 31: Global AI in Drug Discovery Market Value (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031

    Figure 32: Global AI in Drug Discovery Market Value (US$ Mn), by Contract Research Organizations, 2017–2031

    Figure 33: Global AI in Drug Discovery Market Value (US$ Mn), by Academics & Research, 2017–2031

    Figure 34: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031

    Figure 35: Global AI in Drug Discovery Market Value Share Analysis, by Region, 2020 and 2031

    Figure 36: Global AI in Drug Discovery Market Attractiveness Analysis, by Region, 2021–2031

    Figure 37: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 38: North America AI in Drug Discovery Market Value Share (%), by Country, 2020 and 2031

    Figure 39: North America AI in Drug Discovery Market Attractiveness Analysis, by Country, 2021–2031

    Figure 40: North America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 41: North America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

    Figure 42: North America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 43: North America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

    Figure 44: North America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 45: North America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 46: North America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 47: North America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 48: North America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 49: North America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 50: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 51: Europe AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 52: Europe AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 53: Europe AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 54: Europe AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

    Figure 55: Europe AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 56: Europe AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

    Figure 57: Europe AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 58: Europe AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 59: Europe AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 60: Europe AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 61: Europe AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 62: Europe AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 63: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 64: Asia Pacific AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 65: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 66: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 67: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

    Figure 68: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 69: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–203169

    Figure 70: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 71: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 72: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 73: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 74: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 75: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 76: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 77: Latin America AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 78: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 79: Latin America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 80: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–203180

    Figure 81: Latin America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 82: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

    Figure 83: Latin America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 84: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 85: Latin America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 86: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 87: Latin America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 88: Latin America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 89: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 90: Middle East & Africa AI in Drug Discovery Market Value Share (%), by Country/Sub-Region, 2020 and 2031

    Figure 91: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 92: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

    Figure 93: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

    Figure 94: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

    Figure 95: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

    Figure 96: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 97: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 98: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

    Figure 99: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

    Figure 100: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 101: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved